CN113249385A - TLR4 gene deletion zebra fish model - Google Patents
TLR4 gene deletion zebra fish model Download PDFInfo
- Publication number
- CN113249385A CN113249385A CN202110488818.2A CN202110488818A CN113249385A CN 113249385 A CN113249385 A CN 113249385A CN 202110488818 A CN202110488818 A CN 202110488818A CN 113249385 A CN113249385 A CN 113249385A
- Authority
- CN
- China
- Prior art keywords
- tlr4
- fish
- sgrna
- tlr4 gene
- zebra fish
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 241000252212 Danio rerio Species 0.000 title claims abstract description 48
- 101150082427 Tlr4 gene Proteins 0.000 title claims abstract description 27
- 238000012224 gene deletion Methods 0.000 title claims abstract description 15
- 238000000338 in vitro Methods 0.000 claims abstract description 28
- 108020004999 messenger RNA Proteins 0.000 claims abstract description 28
- 108091033409 CRISPR Proteins 0.000 claims abstract description 26
- 238000013518 transcription Methods 0.000 claims abstract description 26
- 230000035897 transcription Effects 0.000 claims abstract description 26
- 108091027544 Subgenomic mRNA Proteins 0.000 claims abstract description 23
- 241000251468 Actinopterygii Species 0.000 claims abstract description 20
- 230000035772 mutation Effects 0.000 claims abstract description 19
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims abstract description 18
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims abstract description 17
- 210000001161 mammalian embryo Anatomy 0.000 claims abstract description 14
- 238000012216 screening Methods 0.000 claims abstract description 14
- 238000003209 gene knockout Methods 0.000 claims abstract description 5
- 238000010354 CRISPR gene editing Methods 0.000 claims abstract description 4
- 206010061218 Inflammation Diseases 0.000 claims abstract description 4
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 4
- 230000004054 inflammatory process Effects 0.000 claims abstract description 4
- 238000009401 outcrossing Methods 0.000 claims abstract description 4
- 230000001568 sexual effect Effects 0.000 claims abstract description 4
- 238000010276 construction Methods 0.000 claims abstract description 3
- 108020005004 Guide RNA Proteins 0.000 claims description 15
- 210000002257 embryonic structure Anatomy 0.000 claims description 7
- 101150038500 cas9 gene Proteins 0.000 claims description 2
- 238000000746 purification Methods 0.000 abstract description 4
- 238000013461 design Methods 0.000 abstract description 2
- 108020004414 DNA Proteins 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 16
- 230000014509 gene expression Effects 0.000 description 15
- 230000000638 stimulation Effects 0.000 description 9
- 102000002689 Toll-like receptor Human genes 0.000 description 8
- 108020000411 Toll-like receptor Proteins 0.000 description 8
- 102100040247 Tumor necrosis factor Human genes 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 238000001976 enzyme digestion Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 238000002156 mixing Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010057466 NF-kappa B Proteins 0.000 description 3
- 102000003945 NF-kappa B Human genes 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241001098657 Pterois Species 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000004720 fertilization Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 108700024526 zebrafish sox32 Proteins 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102000003954 Autophagy-Related Proteins Human genes 0.000 description 1
- 108010082399 Autophagy-Related Proteins Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102100035102 E3 ubiquitin-protein ligase MYCBP2 Human genes 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 101150101999 IL6 gene Proteins 0.000 description 1
- 108010034143 Inflammasomes Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 description 1
- 108091005906 Type I transmembrane proteins Proteins 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 231100000221 frame shift mutation induction Toxicity 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000017448 oviposition Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 102000007863 pattern recognition receptors Human genes 0.000 description 1
- 108010089193 pattern recognition receptors Proteins 0.000 description 1
- 238000002205 phenol-chloroform extraction Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008263 repair mechanism Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/89—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/40—Fish
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0368—Animal model for inflammation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Environmental Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Medicinal Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention relates to construction of a TLR4 gene-deleted zebra fish, which comprises the following specific steps of CRISPR/Cas9 gene knockout target site design; constructing an sgRNA in-vitro transcription vector; in vitro transcription, purification and identification of sgRNA; preparing Cas9 mRNA; screening sgRNA with highest mutation efficiency for obtaining F0An embryo, the sgRNA sequence being 5'-GCCTCTAACGATATAGATGA-3'; f is to be0Feeding the embryo to sexual maturity; outcrossing with wild adult fish, screening F0(ii) a Selection of F producing efficient mutations0Selfing and screening F1(ii) a From F1Selecting female fish and male fish with the same mutation from the generation mutants, and hybridizing to obtain F2Generation; the constructed zebra fish with the TLR4 gene deletion can be stably inherited, and the zebra fish with the TLR4 gene deletion can be used for researching the relation between the TLR4 gene and inflammation and tumors.
Description
Technical Field
The invention belongs to the field of molecular biology, and particularly relates to a TLR4 gene deletion zebra fish model.
Background
Toll-like receptor 4 (TLR 4) belongs to type I transmembrane protein receptor, is a key regulator of innate immunity and adaptive immune system, can directly mediate body reaction with pathogens, TLR4 is the earliest discovered TLRs family member, is a pattern recognition receptor involved in infectious and autoimmune diseases, and can be divided into exogenous pathogen-associated molecular patterns (PAMPs) and endogenous loss-associated molecular patterns (DAMPs) according to the source of its ligand. TLR 4/NF-kB is a classical inflammation signal pathway, and can reduce the release of inflammatory mediators by inhibiting the TLR 4/NF-kB signal pathway so as to relieve pain, and at present, the relation between the TLR 4/NF-kB signal pathway and inflammasome and autophagy related molecules is to be further researched. TLR4 is related to the occurrence and development of various tumors, changes of the activity of TLR4, and may affect the growth, invasion, metastasis, drug resistance and the like of tumor cells.
The similarity of the zebra fish and the human gene reaches 87%, the once egg laying amount of the zebra fish is large, a plurality of experimental materials can be obtained, the individual body is small, the feeding cost is low, and the zebra fish is a good animal model for researching the gene function.
Disclosure of Invention
The invention aims to construct a TLR4 gene deletion zebra fish model.
The preparation process of the invention is as follows:
the DNA sequence of the target site of the invention is as follows: 5'-GCCTCTAACGATATAGATGA-3' (Seq No. 1).
The invention provides a gene targeting kit, which comprises two Oligo sequences, wherein the Oligo sequences are 5'-ACACCGCCTCTAACGATATAGATGAG-3' (Seq No.2) and 5'-AAAACTCATCTAT ATCGTTAGAGGCG-3' (Seq No.3), and the kit can be used for silencing TLR4 gene expression.
The invention provides a gene knockout method, which comprises the following steps: the Oligo fragment is used for recognizing a target site of a target gene, binding with Cas9 and recognizing a PAM sequence at the target site, guiding nuclease to bind to the target site of the target gene, starting shearing to form a DSB gap, then connecting a cell with a repair mechanism through a non-homologous end to repair a double chain of the target gene, causing frameshift mutation, and finally knocking out the target gene.
Further, the target point is one or more than one.
According to another aspect of the invention, the invention provides a preparation method of zebra fish with the TLR4 gene deleted, which comprises the following steps:
1. determining a TLR4 target site according to a TLR4 gene sequence;
2. designing an Oligo sequence according to a TLR4 target site;
3. constructing a gRNA in vitro transcription vector;
4, PCR to obtain a gRNA in vitro transcription template;
5. carrying out in-vitro transcription on the template obtained in the step 4 to obtain gRNA;
6. preparing an in vitro transcription template of Cas9 mRNA;
7. transcribing Cas9 mRNA in vitro;
8. adding a polyA sequence, and recovering Cas9 mRNA;
9. cas9 mRNA and gRNA are mixed and injected into zebra fish embryos at the single cell stage;
screening the gRNA with the highest mutation efficiency for obtaining F0An embryo, the sgRNA sequence being 5'-GCCTCTA ACGATATAGATGA-3' (Seq No. 1);
10. f is to be0Feeding the embryo to sexual maturity;
11. outcrossing with wild adult fish, screening F0;
12. Selection of F producing efficient mutations0Selfing and screening F1;
13. From F1Selecting female fish and male fish with the same mutation from the generation mutants, and hybridizing to obtain F2Generation;
14. screening TLR4 gene knockout homozygote to obtain the stably inherited TLR4 gene deletion zebra fish.
The invention has the advantages that:
the constructed zebra fish with the TLR4 gene deletion is the first case at home and abroad.
The constructed zebra fish with the TLR4 gene deletion can be stably inherited and can be used for researching the relation between the TLR4 gene and inflammation and tumors.
Drawings
FIG. 1: clone scaffold pGU6 electrophoretogram
FIG. 2: gRNA in vitro transcription template
FIG. 3: in vitro transcription of Cas9 mRNA
FIG. 4: PCR and enzyme digestion identification mutant
FIG. 5: wild type and TLR4 gene deletion zebra fish sequence comparison
FIG. 6: comparison of wild type and TLR 4-deleted zebra fish IL6 expression level after LPS stimulation
FIG. 7: comparison of TNF alpha expression levels of wild type zebra fish with TLR 4-deleted zebra fish after LPS stimulation
FIG. 8: comparison of TNF alpha expression levels of wild type zebra fish with TLR 4-deleted type before LPS stimulation
Detailed Description
The present invention will be described in further detail with reference to the following examples, which are provided only for illustrating the present invention and are not intended to limit the scope of the present invention.
Example 1: preparation of animal models of the invention
1. Laboratory animal
Culturing wild zebra fish (TU strain) according to a standardized scheme, wherein the water temperature is 28.5 ℃, the light/dark cycle is 14 h/10 h, collecting embryos after the adult zebra fish spawns, culturing the adult zebra fish in E3 hatching fluid, and expressing the development stages of the embryos and the young fishes according to hours of fertilization (hpf) or days of fertilization (dpf);
CRISPR/Cas9 Gene knockout target site design
Inquiring a zebra fish TLR4 gene sequence (KC832406.1, Seq No.4) on NCBI, designing TLR4 sgRNA and Oligo sequences according to a CRISPR/Cas9 knockout principle, wherein target sites and the Oligo sequences are shown in Table 1;
TABLE 1 sgRNA and Oligo sequences
3. Construction of gRNA in vitro transcription vector
3.1 using Bsa I to carry out enzyme digestion on pGL3-U6-SgRNA-PGK-Puromycin (hereinafter referred to as pGU6) and carrying out gel cutting recovery (shown in figure 1) to obtain a sgRNA cloning skeleton, wherein the length of the sgRNA cloning skeleton is about 5000bp, and a reaction system is shown in a table 2;
table 2 enzyme digestion system:
3.2 ordering the oligo sequence according to the target site;
3.3 using ddH2O respectively dissolving the oligos into 10 mu M solution, annealing to obtain small viscous terminal fragments, wherein the annealing reaction system is shown in Table 3;
TABLE 3 annealing procedure
3.4 connecting and transforming the annealed fragment with the recovered sgRNA cloning framework, selecting positive clones to be sequenced, selecting clone glycerol with correct sequence for bacterium conservation and quality improvement, wherein the connection system is shown in Table 4;
TABLE 4 connection System
4. Preparation of sgRNA
4.1 order primer sequence T7-sgRNA-F: TTAATACGACTCACTCACTATAGGCCTCTAACGA TATAGATGAG-3' (Seq No.11), sgRNA-R: AAGAATGTGCGAGTCCCAGG (Seq number 12); performing PCR amplification according to the following reaction and reaction program, wherein the reaction system is 50 μ L, obtaining a DNA template of sgRNA in vitro transcription, and analyzing and identifying by 2% agarose gel electrophoresis, about 470bp (shown in figure 2), the PCR reaction system is shown in Table 5, the PCR reaction program is pre-deformed at 95 ℃ for 5min, the PCR reaction program is repeated for 30 cycles (94 ℃ 30s, 52 ℃ 30s and 72 ℃ 30s), the PCR reaction program is 5min at 72 ℃ and 1h at 4 ℃;
TABLE 5 PCR reaction System
Components | Sample addition amount |
10×5 PCR buffer | 5μL |
25mM MgSO4 | 5μL |
2mM dNTPs | 5μL |
T4-sgRNA-F(10μM) | 1μL |
sgRNAr-R(10μM) | 1μL |
pGU6-sgRNA | 10ng |
X5 High-Fidelity DNA polymerase | 1uL |
ddH2O | 50μL |
4.2 in vitro transcription template for purification of sgRNA
4.2.1 adding chloroform/phenol/isopropanol mixed solution with the same volume into the PCR product, and uniformly mixing;
4.2.24 ℃, 16000g centrifugation for 5min, carefully suction supernatant into new EP tube;
4.2.3 adding 1/10 volume of 3mM NaAC, mixing, adding 2 times volume of anhydrous ethanol, mixing, standing at-80 deg.C for at least 1h, taking out, centrifuging at 4 deg.C and 16000g for 30 min;
4.2.4 carefully discard the supernatant, wash the precipitate with 70% ethanol 3 times, each time with 200. mu.L, wash at 4 ℃ and centrifuge at 16000g for 5 min;
4.2.5 washing with 400 μ L anhydrous ethanol, taking away residual salt solution, sucking up liquid, and drying at room temperature for 5-10min to volatilize ethanol;
4.2.6 adding appropriate amount of non-RNA water to dissolve according to the amount of precipitate, and measuring the concentration;
4.3 in vitro transcription, purification and identification of sgRNA
Using MEGAshortscriptTMThe Kit in vitro transcription Kit performs in vitro transcription of sgRNA according to the following reaction system, the reaction system is shown in table 6, the reaction conditions are 37 ℃ and 4 hours, after the in vitro transcription is finished, 4.5 mu L of DNase is added, the reaction is performed for 20min at 37 ℃, a DNA template is removed, after the reaction is finished, 480 mu L of nucleic-free Water is added, the purification is performed by using a phenol chloroform extraction method, the RNase-free Water is added to dissolve RNA precipitate, the concentration is not lower than 500 ng/mu L, the RNA is subpackaged, and the purified RNA is subjected to electrophoresis identification by using 2% agarose gel;
the sgRNA in vitro transcription system is shown in table 6;
TABLE 6 in vitro transcription sgRNA reaction System
Components | Sample addition amount |
NTPs | 8μL |
In vitro transcription of DNA templates | 7μL |
T7 Enzyme Mix | 2uL |
10×T7 Reaction Buffer | 2μL |
Nuclease-free Water | To 20μl |
5. Preparation of Cas9 mRNA
5.1 preparation of in vitro transcription template for Cas9 mRNA: the pSP6-2sNLS-spC as9 vector (37 ℃, 4h or more) was linearized by a single digestion with Xba I; taking a small amount of electrophoresis to confirm that linearization is complete, and directly recovering a linearization product;
5.2 in vitro transcription of Cas9 mRNA, the mRNA in vitro transcription system is shown in Table 7;
TABLE 7 Cas9 mRNA in vitro transcription System
5.3 addition of polyA sequence, system shown in Table 8, recovered mRNA (FIG. 3) for microinjection;
TABLE 8 mRNA plus polyA reaction System
5.3 screening of the highest mutation efficiency gRNAs for F0An embryo, wherein Cas9 mRNA and gRNA are mixed and injected into a single-cell zebra fish embryo, the same batch of uninjected embryos are used as a control, Cas9 mRNA 300-500pg and gRNA 25-200pg are adopted, and the mutation efficiency of each group is shown in Table 9;
table 9 sgRNA mutation efficiency
Serial number | sgRNA sequence | Efficiency (%) |
1 | GAATGAACTTATGGAGAATC(Seq No.5) | 21.35 |
2 | GCCTCTAACGATATAGATGA(Seq No.1) | 39.81 |
3 | GACCCAAGCTTCATCATAGC(Seq No.8) | 18.69 |
As can be seen from table 9, sgRNA No.2, which was the most efficient mutation, was selected for co-injection with Cas9 mRNA for F acquisition0And (3) an embryo.
6. Preparation F0Zebra fish substitute
6.1 Cas9 mRNA and gRNA are mixed and injected into a single-cell zebra fish embryo, and meanwhile, the uninjected embryo of the same batch is used as a control, the Cas9 mRNA 300-500pg and the gRNA 25-200 pg;
6.2 taking embryos with normal phenotype after 2-4dpf injection, extracting genome DNA, and detecting the mutation efficiency of the target site by PCR and T7E1 enzyme digestion (figure 4);
6.3 sequencing the PCR products which can be cut, and detecting the mutation type;
6.4 selection of F for injection in the same batch with higher mutation efficiency and higher survival rate0Feeding the embryo to sexual maturity;
6.5 outcrossing with wild adult fish, 3-5F of 1dpf1Mixing the embryos into a group to extract genome DNA;
6.6 detecting the mutation condition of the target site by PCR and enzyme digestion;
6.7 sequencing the PCR products which can be cut to determine the mutation type;
6.8 selection of F producing potent mutations0Mating fish and breeding in large quantities F1;
7. Screening for F carrying the mutation at the target site1Adult fish
7.1 mixing F1Raising to be large enough until tail fins are suitable to be cut;
7.2F1cutting tail fins of adult fishes, extracting a genome, carrying out gene detection one by one through PCR and enzyme digestion, and screening out an F1 heterozygote;
7.3 sequencing the PCR products which can be cut, and determining the mutation type by sequencing;
8. from F1Selecting female fish and male fish with the same mutation from the generation mutants, and hybridizing to obtain F2Culturing at 28.5 deg.C, taking part of embryo at 4dpf, extracting genome DNA from each embryo, and performing T7E1 enzyme digestion detection;
9. the efficiency of identifying homozygous mutations by PCR banding analysis was further identified by sequencing (figure 5).
Example 2: after LPS stimulation, the wild type is compared with the TLR4 gene deletion zebra fish IL6 and TNF-alpha mRNA expression level
1. Dividing 20 male and female half wild type zebra fishes into two groups, wherein one group is used as a control, the other group is soaked for 2 hours by using 3% LPS, the 20 male and female half TLR4 gene-deleted zebra fishes are also divided into two groups, one group is used as a control, the other group is soaked for 2 hours by using 3% LP S, the groups are anesthetized in an ice water bath after 4 hours, the surface moisture of the fishes is completely absorbed, the tails of the fishes are cut off by using an aseptic surgical scissors, a high-speed refrigerated centrifuge is used for centrifuging at 4 ℃ and 2000r/min for 2 minutes, then blood serum of the 2 fishes is absorbed and mixed, the contents of IL6 and TNF-alpha in the blood and the blood are measured by an ELISA experiment, and then the heart, the liver and the lung are respectively extracted to obtain RNA;
2. after quantifying the RNA extracted in the step 1, 2 mu g of each sample is subjected to RNA reverse transcription, the expression conditions of IL6 and TNF-alpha in the heart, the liver and the lung are respectively measured by quantitative PCR with p-actin as an internal reference, and the reaction conditions are as follows: 3min at 95 ℃; (95 ℃ for 30s, 60 ℃ for 15s, 72 ℃ for 30s)40 cycles; the primer sequences are shown in Table 10 at 95 ℃ for 15s and 60 ℃ for 15 s.
3. Results of the experiment
The real-time quantitative PCR reaction results show (figure 6-8), before stimulation by LPS, the wild type and TLR4 gene-deleted zebra fish can not detect the expression of IL6 mRNA, after stimulation by LPS, the wild type IL6 mRNA expression is obviously increased, the TLR4 gene-deleted zebra fish can still not detect the expression of IL6 mRNA, before and after stimulation by LPS, the expression quantity of the wild type zebra fish TNF-alpha mRNA is obviously increased, but the expression quantity of the TLR4 gene-deleted zebra fish TNF-alpha mRNA is little increased. The TLR4 gene deletion zebra fish TLR4 gene loses efficacy, downstream IL6 gene expression cannot be caused, and compared with wild TLR4 gene expression, the expression is obviously reduced. Furthermore, Elisa experimental results show that IL6 and TLR4 are not detected in the serum of the zebra fish with the deletion of the wild type and TLR4 genes before stimulation of LPS, the content of the wild type IL6 is 598.374 +/-129.22, the content of TNF-alpha is 132.94 +/-43.21, and the expression of IL6 and TLR4 proteins is not detected in the zebra fish with the deletion of the TLR4 genes after stimulation of LPS.
Sequence listing
<110> Guangzhou Bojii Biotechnology Ltd
<120> TLR4 gene deletion zebra fish model
<160> 14
<170> SIPOSequenceListing 1.0
<210> 1
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 1
gcctctaacg atatagatga 20
<210> 2
<211> 26
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 2
acaccgcctc taacgatata gatgag 26
<210> 3
<211> 26
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 3
aaaactcatc tatatcgtta gaggcg 26
<210> 4
<211> 224
<212> DNA
<213> Danio rerio
<400> 4
tatttgcgtt attgttggat tttactaaga ggctacagat cacctggaca gcaagaatgt 60
tcttatgacg catttgtgat attctccagc tatgatgaag cttgggtcat gaatgaactt 120
atggagaatc tggaggtcgg cgcgctacca attcgttttt gccttcacat gcgggacttt 180
caagcaggga agtcaatcgc ctctaacgat atagatgaag gaat 224
<210> 5
<211> 20
<212> DNA
<213> Danio rerio
<400> 5
gaatgaactt atggagaatc 20
<210> 6
<211> 26
<212> DNA
<213> Danio rerio
<400> 6
acaccgaatg aacttatgga gaatcg 26
<210> 7
<211> 26
<212> DNA
<213> Danio rerio
<400> 7
aaaacgattc tccataagtt cattcg 26
<210> 8
<211> 20
<212> DNA
<213> Danio rerio
<400> 8
gacccaagct tcatcatagc 20
<210> 9
<211> 26
<212> DNA
<213> Danio rerio
<400> 9
acaccgaccc aagcttcatc atagcg 26
<210> 10
<211> 26
<212> DNA
<213> Danio rerio
<400> 10
aaaacgctat gatgaagctt gggtcg 26
<210> 11
<211> 44
<212> DNA
<213> Danio rerio
<400> 11
ttaatacgac tcactcacta taggcctcta acgatataga tgag 44
<210> 12
<211> 20
<212> DNA
<213> Danio rerio
<400> 12
aagaatgtgc gagtcccagg 20
<210> 13
<211> 19
<212> DNA
<213> Danio rerio
<400> 13
tcgtgtggct ctagtatga 19
<210> 14
<211> 21
<212> DNA
<213> Danio rerio
<400> 14
ccttgttata gtgctcttga c 21
Claims (2)
1. The construction method of the zebra fish with the TLR4 gene deletion is characterized by comprising the following steps:
1) determining a TLR4 target site according to a TLR4 gene sequence, and designing the target site according to a CRISPR/Cas9 knockout principle;
2) designing an Oligo sequence according to a TLR4 target site;
3) constructing a gRNA in vitro transcription vector;
4) PCR is carried out to obtain a gRNA in vitro transcription template;
5) carrying out in-vitro transcription on the template obtained in the step 4 to obtain gRNA;
6) preparing an in vitro transcription template of Cas9 mRNA;
7) transcribing Cas9 mRNA in vitro;
8) adding a polyA sequence, and recovering Cas9 mRNA;
9) cas9 mRNA and sgRNA are mixed and injected into zebra fish embryos at the single cell stage;
10) screening sgRNA with highest mutation efficiency for obtaining F0An embryo, the sgRNA sequence being 5'-GCCTCTAACGATATAGATGA-3';
11) f is to be0Feeding the embryo to sexual maturity;
12) outcrossing with wild adult fish, screening F0;
13) Selection of F producing efficient mutations0Selfing and screening F1;
14) From F1Selecting female fish and male fish with the same mutation from the generation mutants, and hybridizing to obtain F2Generation;
15) screening TLR4 gene knockout homozygote to obtain the stably inherited TLR4 gene deletion zebra fish.
2. The use of the TLR4 gene-deleted zebrafish of claim 1, which is used for studying the relationship of TLR4 gene with inflammation and tumor.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110488818.2A CN113249385A (en) | 2021-04-30 | 2021-04-30 | TLR4 gene deletion zebra fish model |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110488818.2A CN113249385A (en) | 2021-04-30 | 2021-04-30 | TLR4 gene deletion zebra fish model |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113249385A true CN113249385A (en) | 2021-08-13 |
Family
ID=77223594
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110488818.2A Withdrawn CN113249385A (en) | 2021-04-30 | 2021-04-30 | TLR4 gene deletion zebra fish model |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113249385A (en) |
-
2021
- 2021-04-30 CN CN202110488818.2A patent/CN113249385A/en not_active Withdrawn
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107475300B (en) | Construction method and application of Ifit3-eKO1 gene knockout mouse animal model | |
AU2017101108A4 (en) | Construction method of animal model of mucopolysaccharidosis type II and use thereof | |
CN108707629A (en) | The preparation method of zebra fish notch1b gene mutation bodies | |
CN110551759A (en) | Composition and method for improving recombination efficiency of transgenic cells | |
CN110129453B (en) | Method for identifying genotype of fast and slow feathers of chicken | |
CN102653756B (en) | Directional modification method of specific gene of animal genome and application thereof | |
CN108753834B (en) | Preparation method of zebra fish mutant with ddx27 gene deletion | |
CN110643636A (en) | Megalobrama amblycephala MSTNa & b gene knockout method and application | |
CN113736787A (en) | gRNA of targeted mouse Atp7b gene and method for constructing Wilson disease mouse model | |
CN113088521A (en) | Construction method of Ahnak2 gene knockout animal model based on CRISPR/Cas9 technology | |
CN110066805A (en) | The method of gene knockout breeding adgrf3b Gene Deletion zebra fish | |
CN113234756A (en) | Construction method of LAMA3 gene knockout animal model based on CRISPR/Cas9 technology | |
CN113249385A (en) | TLR4 gene deletion zebra fish model | |
CN113249409A (en) | BMI1 gene-deleted zebra fish | |
CN112695034A (en) | Preparation method of zebra fish with ApoE gene deletion | |
CN109694885B (en) | Method for preparing PI3K gamma whole-body knockout mode mouse based on CRISPR/Cas9 technology, application thereof and kit | |
CN114480497A (en) | Construction method and application method of ep400 gene knockout zebra fish heart failure model | |
CN112680479A (en) | Preparation method of zebra fish with CYP1B1 gene deletion | |
CN110438159A (en) | A kind of construction method for the mutant mouse model causing muscle fibril myopathy | |
CN112980881A (en) | Construction method and application of Arvcf gene knockout animal model | |
CN112899279A (en) | Method for constructing Fzd6 gene knockout mouse model and application | |
CN111893119A (en) | Method for obtaining SCD1 gene editing goat embryo by CRISPR/Cas9 system and microinjection | |
CN111518837A (en) | Mouse with ADRB3 gene knocked out and application thereof | |
CN110331172B (en) | Method for constructing whitened hamster model based on CRISPR-Cas9 system | |
CN114891786B (en) | Dog Rosa26 gene and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20210813 |
|
WW01 | Invention patent application withdrawn after publication |